• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Biden ’ s Physical Says He ’ s ‘ Healthy ’ and ‘ Vigorous, ’ But ‘ Gait Remains Stiff ’
President Biden, who turned 80 in November, was examined by doctors at Walter Reed National Medical Center in Maryland on Thursday. It was his first check up in over a year. Biden, the oldest President in US history, is widely expected to announce in the coming months that he is running for re-election. What were the results? His physician gave him a clean bill of health, but noted Biden continues to have stiffness in his walk from a combination of arthritis in his back, neuropathy in his feet and the long-term effects of breaking his foot in November 2020 while playing with his former dog Major. Doctors conducted a routin...
Source: TIME: Health - February 16, 2023 Category: Consumer Health News Authors: Brian Bennett Tags: Uncategorized Joe Biden Longevity White House Source Type: news

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
CONCLUSION: In tofacitinib-treated patients with PsA/PsO, increased ASCVD risk and baseline MetS were associated with higher IRs for MACE and malignancies. Our results support assessing CV risk in patients with PsA/PsO and suggest enhanced cancer monitoring in those with increased ASCVD risk.REGISTRATION CLINICALTRIALSGOV: NCT01877668/NCT01882439/NCT01976364/NCT00678210/NCT01710046/NCT01241591/NCT01186744/NCT01276639/NCT01309737/NCT01163253.PLAIN LANGUAGE SUMMARY: People who have psoriatic arthritis or psoriasis may have more heart-related problems and cancer if they have a higher risk of cardiovascular disease: A study in...
Source: Adv Data - February 13, 2023 Category: Epidemiology Authors: Lars E Kristensen Bruce Strober Denis Poddubnyy Ying-Ying Leung Hyejin Jo Kenneth Kwok Ivana Vranic Dona L Fleishaker Lara Fallon Arne Yndestad Dafna D Gladman Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Increasing Upstream Chromatin Long –Range Interactions May Favor Induction of Circular RNAs in LysoPC-Activated Human Aortic Endothelial Cells
We examined the sponging potential of all significantly changed circRNAs using the CircInteractome database (Montefiori et al., 2018), recording two miRNAs with four or more predicted binding sites in a single circRNA transcript, a threshold above which meaningful sponging activity is likely to occur Memczak et al. (2013). Another four significantly changed circRNAs are experimentally shown to sponge miRNAs (Dudekula et al., 2016; Chen et al., 2017; Yan et al., 2017; Wang et al., 2018), for six total circRNAs with miRNA sponging activity including miR125, miR143, miR1272, miR153, miR515-5p, and miR196a-5p (Table 4). In Fig...
Source: Frontiers in Physiology - April 17, 2019 Category: Physiology Source Type: research

Anti-inflammatory drug may help prevent heart attacks
Conclusion This well-conducted study shows promising signs that canakinumab may reduce the risk of future heart attacks and other cardiovascular events in people who've had them in the past. But before any changes are made to the current licensing of this drug, further research is needed to confirm the beneficial effects and the optimal dose. Most importantly, researchers will need to focus on the observation that the drug lowered white blood cell counts and increased the risk of fatal infection. They estimated around 1 in every 300 people taking canakinumab would die of a fatal infection. This number, while low, is sti...
Source: NHS News Feed - August 30, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

7 Foot Problems That Can Be Serious
If you want to know the state of your health, try looking down. “There’s no question it’s extremely important that people pay attention to their feet,” says Terry Philbin, D.O., spokesperson for the American Academy of Orthopedic Surgeons (AAOS) and a foot and ankle specialist at the Orthopedic Foot and Ankle Center in Westerville, Ohio. The condition of your feet can give you clues to a host of medical issues, such as diabetes, arthritis, and even heart disease. Read on to find out what to look for and what it may mean. 1. Pain “There’s no pain that should be ignored,” says Jane ...
Source: Healthy Living - The Huffington Post - November 12, 2016 Category: Consumer Health News Source Type: news

Rooibos: Better Than Green Tea For Many Reasons
When I hiked Table Mountain on my last trip to South Africa, the locals told me about an herb that is better than green tea that kept them disease-free. African Bushmen have used this herb since before recorded history, but it’s still pretty rare here in America. Studies on this plant are being done all over the world. But not in the U.S. Because Big Pharma and the FDA aren’t interested in a natural cure that can’t be patented — or profited from. What is This South African Herb? I’m talking about an herb called Rooibos — or red bush in Afrikaans. Rooibos (pronounced roy-boss) provides a whole lo...
Source: Al Sears, MD Natural Remedies - May 27, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Natural Cures Source Type: news

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial
ConclusionsTildrakizumab had treatment effects that were superior to placebo, maintained for 52 weeks of treatment, and persisted for 20 weeks after cessation. Tildrakizumab was generally safe and well tolerated. These results suggest that IL‐23p19 is a key target for suppressing psoriasis.
Source: British Journal of Dermatology - October 15, 2015 Category: Dermatology Authors: K. Papp, D. Thaçi, K. Reich, E. Riedl, R.G. Langley, J.G. Krueger, A.B. Gottlieb, H. Nakagawa, E.P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames Tags: Clinical Trials Source Type: research

Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial.
CONCLUSIONS: Tildrakizumab demonstrated superior efficacy vs. placebo that was maintained up to 52 weeks of treatment and for an additional 20 weeks after cessation of study therapy. Tildrakizumab was generally safe and well tolerated. These results suggest that IL-23p19 is a key target for suppressing psoriasis. ClinicalTrials Registry # NCT01225731 This article is protected by copyright. All rights reserved. PMID: 26042589 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - June 3, 2015 Category: Dermatology Authors: Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R Tags: Br J Dermatol Source Type: research

Tildrakizumab (MK‐3222), an Anti‐ IL‐23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo‐ Controlled Trial
ConclusionsTildrakizumab demonstrated superior efficacy vs. placebo that was maintained up to 52 weeks of treatment and for an additional 20 weeks after cessation of study therapy. Tildrakizumab was generally safe and well tolerated. These results suggest that IL‐23p19 is a key target for suppressing psoriasis. ClinicalTrials Registry # NCT01225731This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - June 1, 2015 Category: Dermatology Authors: K. Papp, D. Thaçi, K. Reich, E. Riedl, R.G. Langley, J.G. Krueger, A.B. Gottlieb, H. Nakagawa, E.P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames Tags: Original Article Source Type: research

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Conclusions Among RA patients, there is a high prevalence of comorbidities and their risk factors. In this multinational sample, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities. Systematic measurement of vital signs and laboratory testing detects otherwise unrecognised comorbid conditions.
Source: Annals of the Rheumatic Diseases - December 4, 2013 Category: Rheumatology Authors: Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M. H., Casado, G., Detert, J., El-zorkany, B., Emery, P., Hajjaj-Hassouni, N., Harigai, M., Luo, S.-F., Kurucz, R., Maciel, G., Mola, E. M., Montecucco, C. M., McInnes, I., Radner, H., Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Osteoporosis, Rheumatoid arthritis, Epidemiology, Calcium and bone Clinical and epidemiological research Source Type: research

Time trends of incidence of age-associated diseases in the US elderly population: medicare-based analysis
Conclusion: time trends of the incidence of diseases common in the US elderly population were evaluated. The results show dramatic increase in incidence rates of melanoma, goiter, chronic renal and Alzheimer's disease in 1992–2005. Besides specifying widely recognised time trends on age-associated diseases, new information was obtained for trends of asthma, ulcer and goiter among the older adults in the USA.
Source: Age and Ageing - June 17, 2013 Category: Geriatrics Authors: Akushevich, I., Kravchenko, J., Ukraintseva, S., Arbeev, K., Yashin, A. I. Tags: Research Papers Source Type: research